1218P - Characterization of GI toxicities and their impact on efficacy in patients (pts) with EGFR exon 20 insertion+ (ex20ins+) non-small cell lung cancer (NSCLC) treated with mobocertinib (TAK-788) who previously received platinum chemotherapy

https://oncologypro.esmo.org/meeting-resources/esmo-congress-2021/characterization-of-gi-toxicities-and-their-impact-on-efficacy-in-patients-pts-with-egfr-exon-20-insertion-ex20ins-non-small-cell-lung-cancer

  1231P - Characterization and management of mobocertinib (TAK-788) induced skin toxicity in patients with EGFR exon 20 insertion+ (ex20ins+) non-small cell lung cancer (NSCLC) who previously received platinum chemotherapy

https://oncologypro.esmo.org/meeting-resources/esmo-congress-2021/characterization-and-management-of-mobocertinib-tak-788-induced-skin-toxicity-in-patients-with-egfr-exon-20-insertion-ex20ins-non-small-cell

  1246P - A phase I dose-escalation study of mobocertinib (TAK-788), an oral tyrosine kinase inhibitor (TKI), in Japanese NSCLC patients

https://oncologypro.esmo.org/meeting-resources/esmo-congress-2021/a-phase-i-dose-escalation-study-of-mobocertinib-tak-788-an-oral-tyrosine-kinase-inhibitor-tki-in-japanese-nsclc-patients

  1224P - Systematic review and meta-analysis of immunotherapy effectiveness for pretreated patients with non-small cell lung cancer harboring EGFR exon 20 insertions

https://oncologypro.esmo.org/meeting-resources/esmo-congress-2021/systematic-review-and-meta-analysis-of-immunotherapy-effectiveness-for-pretreated-patients-with-non-small-cell-lung-cancer-harboring-egfr-exon-20-i

  1211P - Indirect comparison of mobocertinib and standard of care in platinum-pretreated patients with NSCLC with EGFR exon 20 insertion

https://oncologypro.esmo.org/meeting-resources/esmo-congress-2021/indirect-comparison-of-mobocertinib-and-standard-of-care-in-platinum-pretreated-patients-with-nsclc-with-egfr-exon-20-insertion